Investigational drug · Phase 3
BXOS110
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for AIS.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BXOS110"
First trial start
2026
Jan 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BXOS110", any sponsor or status.
Conditions studied
As listed on its trial records.
- AIS
Largest trials
Live from ClinicalTrials.gov: studies naming "BXOS110" as an intervention, largest first.
- A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.Pivotal-lookingRecruiting
Biocells (Beijing) Biotech Co.,LtdIndustry
NCT07520565 · 1,112 participants (planned) · Start Jan 19, 2026 · Primary completion Jul 2027
Drug: BXOS110; placebo · For: AIS
Sites: Hengshui, China; Daqing, China; Nanyang, China · 9 sites in all
- BXOS110 Injection in the Treatment of Acute Ischaemic StrokePivotal-lookingStatus unknown
Biocells (Beijing) Biotech Co.,LtdIndustry
NCT06322394 · 300 participants (planned) · Start Feb 7, 2024 · Primary completion Mar 2025
Drug: high-dose BXOS110; low-dose BXOS110 and 1 more · For: Acute Ischemic Stroke
Sites: Shaoguan, China; Hengshui, China; Shijiazhuang, China · 24 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The novel PSD-95 inhibitor BXOS110 provides neuroprotection in acute ischemic stroke.
Zheng HY, Ding YR, Guo FY, et al. · Neuropharmacology 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.